Tabramycin PARI for CF in EUMarch 7, 2019
The European Medicines Agency has approved tobramycin (Tobramycin PARI) a new hybrid medicine for the treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis (CF).
Tobramycin is an aminoglycoside antibiotic which primarily affects bacterial protein synthesis resulting in rapid concentration-dependent bacterial cell death.
Tobramycin PARI is a hybrid medicine of TOBI nebuliser solution which has been authorised in the EU since 10 December 1999. However, the new product contains a different strength of tobramycin and is administered using a different nebuliser device, allowing it to be inhaled over a shorter period.
According to EMA, Tobramycin PARI is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF).